{"id":7862,"date":"2024-12-02T20:58:50","date_gmt":"2024-12-02T12:58:50","guid":{"rendered":"https:\/\/regask.com\/?p=7862"},"modified":"2024-12-02T20:58:50","modified_gmt":"2024-12-02T12:58:50","slug":"aprobacion-de-la-revision-de-medicamentos-de-la-nmpa-en-china","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/china-nmpa-drug-review-approval\/","title":{"rendered":"La NMPA aprueba la primera solicitud de ensayo cl\u00ednico bajo el programa Pi\u2026"},"content":{"rendered":"<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"2451705a-75cb-46e1-baee-db0ea4fb0cfa\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>On November 15, 2024, China\u2019s National Medical Products Administration (NMPA) announced a milestone in its pilot program designed to optimize the review and approval processes for innovative drugs. This initiative aims to streamline clinical trial applications, improving both efficiency and quality.<\/p>\n<h4>Key Highlights<\/h4>\n<ul>\n<li><strong>First Approval:<\/strong><br \/>\nThe first clinical trial application approved under the pilot program is for an injectable drug for advanced solid tumors. The trial will be conducted by <strong>Peking University Cancer Hospital<\/strong>.<\/li>\n<li><strong>Faster Review Process:<\/strong><br \/>\nThe review was completed in just <strong>21 days<\/strong>, showcasing a significant improvement in processing times compared to traditional procedures.<\/li>\n<li><strong>Scope of the Pilot Program:<\/strong>\n<ul>\n<li>A total of <strong>nine clinical trials<\/strong> have been included in the pilot work plan.<\/li>\n<li>Five of these trials have submitted Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE), all of which have been accepted for review.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Enhanced Collaboration:<\/strong><br \/>\nThe program prioritizes closer communication and collaboration among evaluation agencies, local regulatory authorities, applicants, and medical institutions. This approach aims to maintain high-quality standards while expediting the application process.<\/li>\n<\/ul>\n<h4>Implications<\/h4>\n<p>The successful approval under this pilot program marks a promising step in <a href=\"https:\/\/regask.com\/china-cosmetics-monitoring-focus\/\">China\u2019s efforts<\/a> to encourage innovation in drug development. By significantly reducing review timelines and fostering collaboration, the initiative supports the rapid advancement of treatments for critical conditions like advanced tumors.<\/p>\n<h4>Next Steps<\/h4>\n<p>Stakeholders should monitor the progress of the pilot program and its impact on clinical trial efficiency. Companies planning to develop innovative drugs in China may find this program beneficial and should explore opportunities to participate in similar initiatives.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\">\n<div class=\"flex items-center\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>El 15 de noviembre de 2024, la Administraci\u00f3n Nacional de Productos M\u00e9dicos de China (NMPA) anunci\u00f3 un hito en su programa piloto dise\u00f1ado para optimizar los procesos de revisi\u00f3n y aprobaci\u00f3n de medicamentos innovadores. Esta iniciativa busca agilizar las solicitudes de ensayos cl\u00ednicos, mejorando tanto la eficiencia como la calidad. Aspectos destacados: Primera aprobaci\u00f3n: La primera solicitud de ensayo cl\u00ednico aprobada bajo el programa piloto\u2026<\/p>","protected":false},"author":30,"featured_media":7872,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[497,498,591],"class_list":["post-7862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-oncology","tag-drug-development-regs","tag-clinical-trial-regulations"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China NMPA&#039;s New Drug Review &amp; Approval Process | RegASK<\/title>\n<meta name=\"description\" content=\"China&#039;s NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/aprobacion-de-la-revision-de-medicamentos-de-la-nmpa-en-china\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves First Clinical Trial Application Under Pilot Program for Innovative Drugs\" \/>\n<meta property=\"og:description\" content=\"China&#039;s NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/aprobacion-de-la-revision-de-medicamentos-de-la-nmpa-en-china\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T12:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Amandine Tricou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amandine Tricou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"},\"author\":{\"name\":\"Amandine Tricou\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c2135b6dbdb95b0886564618fe9f4108\"},\"headline\":\"NMPA Approves First Clinical Trial Application Under Pi&hellip;\",\"datePublished\":\"2024-12-02T12:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"keywords\":[\"Oncology\",\"Drug Development Regs\",\"Clinical Trial Regulations\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\",\"name\":\"China NMPA's New Drug Review & Approval Process | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"datePublished\":\"2024-12-02T12:58:50+00:00\",\"description\":\"China's NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"width\":800,\"height\":600,\"caption\":\"Nmpa Approves First Clinical Trial Application Under Pilot Program Innovative Drugs\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c2135b6dbdb95b0886564618fe9f4108\",\"name\":\"Amandine Tricou\",\"sameAs\":[\"http:\\\/\\\/www.regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Proceso de revisi\u00f3n y aprobaci\u00f3n de nuevos f\u00e1rmacos de la NMPA de China | RegASK","description":"La NMPA de China introduce un nuevo proceso de revisi\u00f3n y aprobaci\u00f3n de medicamentos, reduciendo el tiempo total de revisi\u00f3n a tan solo 21 d\u00edas. Lea m\u00e1s en RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/aprobacion-de-la-revision-de-medicamentos-de-la-nmpa-en-china\/","og_locale":"es_ES","og_type":"article","og_title":"NMPA Approves First Clinical Trial Application Under Pilot Program for Innovative Drugs","og_description":"China's NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.","og_url":"https:\/\/regask.com\/es\/aprobacion-de-la-revision-de-medicamentos-de-la-nmpa-en-china\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-12-02T12:58:50+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","type":"image\/png"}],"author":"Amandine Tricou","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Amandine Tricou","Est. reading time":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#article","isPartOf":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/"},"author":{"name":"Amandine Tricou","@id":"https:\/\/regask.com\/#\/schema\/person\/c2135b6dbdb95b0886564618fe9f4108"},"headline":"NMPA Approves First Clinical Trial Application Under Pi&hellip;","datePublished":"2024-12-02T12:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/"},"wordCount":266,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","keywords":["Oncology","Drug Development Regs","Clinical Trial Regulations"],"articleSection":["Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/","url":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/","name":"Proceso de revisi\u00f3n y aprobaci\u00f3n de nuevos f\u00e1rmacos de la NMPA de China | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","datePublished":"2024-12-02T12:58:50+00:00","description":"La NMPA de China introduce un nuevo proceso de revisi\u00f3n y aprobaci\u00f3n de medicamentos, reduciendo el tiempo total de revisi\u00f3n a tan solo 21 d\u00edas. Lea m\u00e1s en RegASK.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/china-nmpa-drug-review-approval\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","width":800,"height":600,"caption":"Nmpa Approves First Clinical Trial Application Under Pilot Program Innovative Drugs"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Habilitando decisiones regulatorias m\u00e1s inteligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/c2135b6dbdb95b0886564618fe9f4108","name":"Amandine Tricou","sameAs":["http:\/\/www.regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/7862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=7862"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/7862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/7872"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=7862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=7862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=7862"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}